Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.
Aged
Aged, 80 and over
Antibody Formation
/ immunology
Antigens, Neoplasm
/ immunology
Autoantibodies
/ immunology
B-Lymphocytes
/ immunology
Carcinoma, Pancreatic Ductal
/ blood
Cell Line, Tumor
Cohort Studies
Complement System Proteins
/ immunology
Datasets as Topic
Exosomes
/ immunology
Female
Gene Expression Profiling
Healthy Volunteers
Humans
Male
Microscopy, Electron
Middle Aged
Pancreatic Neoplasms
/ blood
Proteomics
/ methods
Sequence Analysis, RNA
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
16 01 2019
16 01 2019
Historique:
received:
24
01
2018
accepted:
12
12
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
21
3
2019
Statut:
epublish
Résumé
Although B cell response is frequently found in cancer, there is little evidence that it alters tumor development or progression. The process through which tumor-associated antigens trigger humoral response is not well delineated. We investigate the repertoire of antigens associated with humoral immune response in pancreatic ductal adenocarcinoma (PDAC) using in-depth proteomic profiling of immunoglobulin-bound proteins from PDAC patient plasmas and identify tumor antigens that induce antibody response together with exosome hallmark proteins. Additional profiling of PDAC cell-derived exosomes reveals significant overlap in their protein content with immunoglobulin-bound proteins in PDAC plasmas, and significant autoantibody reactivity is observed between PDAC cell-derived exosomes and patient plasmas compared to healthy controls. Importantly, PDAC-derived exosomes induce a dose-dependent inhibition of PDAC serum-mediated complement-dependent cytotoxicity towards cancer cells. In summary, we provide evidence that exosomes display a large repertoire of tumor antigens that induce autoantibodies and exert a decoy function against complement-mediated cytotoxicity.
Identifiants
pubmed: 30651550
doi: 10.1038/s41467-018-08109-6
pii: 10.1038/s41467-018-08109-6
pmc: PMC6335434
doi:
Substances chimiques
Antigens, Neoplasm
0
Autoantibodies
0
Complement System Proteins
9007-36-7
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
254Subventions
Organisme : NCI NIH HHS
ID : P50 CA221707
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100632
Pays : United States
Organisme : NIH HHS
ID : U01 CA200468
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA086368
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196403
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200468
Pays : United States
Organisme : NIH HHS
ID : U01 CA196403
Pays : United States
Références
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
Science. 2008 Feb 29;319(5867):1244-7
pubmed: 18309083
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Immunol Immunother. 2011 May;60(5):639-48
pubmed: 21293856
J Proteome Res. 2006 Feb;5(2):277-86
pubmed: 16457593
FEBS J. 2009 Dec;276(23):6880-904
pubmed: 19860826
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
J Cell Physiol. 2012 Feb;227(2):658-67
pubmed: 21465472
Clin Chim Acta. 2016 Jan 30;453:48-55
pubmed: 26656310
Oncotarget. 2017 Sep 8;8(56):95466-95480
pubmed: 29221141
J Immunol. 2011 Aug 1;187(3):1281-8
pubmed: 21705625
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
J Natl Cancer Inst. 2015 May 29;107(8):
pubmed: 26025324
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
J Immunol. 2013 Mar 15;190(6):2712-9
pubmed: 23418627
Clin Cancer Res. 2000 Oct;6(10):3949-56
pubmed: 11051243
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
Curr Opin Immunol. 1997 Oct;9(5):709-16
pubmed: 9368781
J Transl Med. 2012 Jun 27;10:134
pubmed: 22738135
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Cancer Res. 2015 Aug 15;75(16):3246-54
pubmed: 26088128
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1555-64
pubmed: 26929325
FEBS J. 2011 Apr;278(7):1064-74
pubmed: 21261815
Blood. 2009 Mar 19;113(12):2673-83
pubmed: 19176319
Nature. 2015 May 7;521(7550):94-8
pubmed: 25924065
Cancer Res. 2016 Oct 1;76(19):5597-5601
pubmed: 27634765
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
Cancer Discov. 2016 Mar;6(3):230-2
pubmed: 26951836
Cancer Res. 2013 Mar 1;73(5):1502-13
pubmed: 23269276
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
J Hematol Oncol. 2013 Sep 06;6:67
pubmed: 24010981
Bioinformatics. 2002 Jan;18(1):207-8
pubmed: 11836235
Oncoimmunology. 2013 Jun 1;2(6):e24533
pubmed: 23894715
Clin Cancer Res. 2010 Mar 15;16(6):1781-9
pubmed: 20215540
Front Oncol. 2014 Feb 18;4:32
pubmed: 24600588
Ann Oncol. 2018 Jan 1;29(1):223-229
pubmed: 29045505
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2161-81
pubmed: 24057574
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
EMBO Mol Med. 2013 Feb;5(2):235-49
pubmed: 23165896
Oncotarget. 2016 Mar 8;7(10):11151-64
pubmed: 26840568
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50
pubmed: 15572756